indirect sandwich ELISA assay that is capable of detecting low levels of the polysaccharide antigen of Streptococcus pneumoniae type 3 in clinical samples of human spinal fluid, urine, serum, and sputum. This assay appears promising for a rapid and accurate method of diagnosing serious pneumococcal infections.
MATERIALS AND METHODS
Solid phase for assay. Polystyrene balls (0.25 in., ca. 0.6 cm) with specular finish were purchased from the Precision Plastic Ball Co., Chicago, Ill.
Sera. Commercial antisera and normal sera used in these studies were as follows (source): rabbit antipneumococcus serum pool B (Difco Laboratories, Detroit, Mich.); normal rabbit serum (GIBCO Diagnostics, Grand Island, N.Y.); goat anti-rabbit globulin (Miles Laboratories, Elkhart, Ind.); normal horse serum and fetal calf serum (GIBCO). Horse anti-type 3 pneumococcus serum was kindly provided by Philip Baker (National Institutes of Health, Bethesda, Md.).
Antigen. Purified pneumococcus type 3 polysaccharide (SSS-III) was also provided by Philip Baker.
Enzyme-linked globulin conjugate. The immunoglobulin G fraction of goat anti-rabbit globulin (2 mg/ml), obtained by diethylaminoethyl-cellulose chromatography, was conjugated with alkaline phosphatase (Sigma Chemical Co., St. Louis, Mo.), 2 mg/ ml, using glutaraldehyde as described by Avrameas (2) . para-Nitrophenyl phosphate (5-mg tablets, Sigma) was employed as the enzyme substrate.
Reagents. Buffers used were essentially those described by Voller et al. (11) . The phosphate-buffered saline-Tween was modified by addition of 1 ml of DROW AND MANNING Tween 20 per liter. The enzyme substrate, p-nitrophenyl phosphate, was dissolved in diethanolamine buffer (pH 9.8) to a final concentration of 1 mg/ml. The sputum-liquifying agent (Sputolysin) was obtained from Calbiochem, La Jolla, Calif.
Performance of the indirect sandwich ELISA. The steps in the assay, similar to those described previously (7) , are illustrated schematically in Fig. 1 Selection of serum dilutions. A 1:500 dilution of horse anti-SSS-III serum was used routinely, based on preliminary experiments using dilutions of antiserum ranging from 1:50 to 1:2,000. The remaining conditions of the test were: (i) purified antigen concentrations ranging from 1 to 1,000 ng/ml; (ii) a 1:500 dilution of rabbit anti-SSS-III serum, based on a titration in which horse anti-SSS-III was held constant at 1:500, and (iii) a conjugate dilution of 1:200, which in turn was based on results of titrations performed with dilutions of both horse and rabbit antisera held constant at 1:500.
Selection of incubation times and tempera- Results obtained at an SSS-III concentration of 1 ng/ ml were in all cases above the base-line (control) level, but only marginally so. To avoid equivocal readings, estimation of SSS-III concentrations in test specimens should be restricted to that portion of the curve which is clearly above the base line. Thus the absolute lower limit of test sensitivity appears to be 1 ng/ml, but with the above restriction, the practical lower limit of detection is approximately 2 to 3 ng/ml.
RESULTS
Effect of body fluids on the detection of SSS-III. Comparisons of standard curves for purified SSS-Ill diluted in clinical materials (spinal fluid, urine, serum, and sputum) with curves prepared in phosphate-buffered saline are also shown in Fig. 2 . All of the standard curves were essentially similar, although those for the clinical materials showed slightly reduced sensitivity, especially in the case of sputum.
Tests with human clinical specimens culture negative for S. pneumoniae. A series of tests was performed on clinical specimens that were culture negative for pneumococcus; all such tests gave results below the base-line level (generally, absorbances less than 0.07). Specifically, 15 spinal fluids that were bacterial culture negative produced absorbances ranging from 0.01 to 0.03, and 15 sera and 5 urines submitted for routine tests gave absorbances ranging between 0.01 and 0.06. Five individual sputum specimens that contained only a mixture of normal oropharyngeal flora produced absorbances between 0.01 and 0.07.
Detection of S. pneumoniae organisms. To determine whether S. pneumoniae could be detected in clinical specimens, viable organisms were added to normal sputum pools. Absorbances between 0.02 and 0.03 were obtained in tests of the unaltered sputum pools, whereas values between 0.60 and 0.70 were obtained routinely with specimens containing 106 colonyforming units of S. pneumoniae type 3 per ml. Absorbances of 0.60 to 0.70 correspond to concentrations of approximately 100 ng of purified SSS-III polysaccharide per ml. This agrees with observations by Coonrod and Drennan (6), who detected pneumococcal antigen in human clinical specimens by using counterimmunoelectrophoresis. They reported detection of 50 to 100 ng of pneumococcal polysaccharide per ml by using 106 pneumococci per ml.
Tests for cross-reactions by other orga- An ELISA test similar in principle to the one reported here but differing in several important aspects has been reported very recently (9) . Both assays have the advantages of being about 25 times more sensitive than counterimmunoelectrophoresis, and of detecting pneumococcal antigen, thus permitting diagnosis before detectable antibody has developed. The assay described here, however, has several additional advantages. Results with polystyrene balls are available within 3 h, rather than 7 h as described for the use of microtiter plates (9) . Moreover, this ELISA technique can readily be adapted to screening panels in which not only individual serotypes of pneumococcus but also other species of organisms involved in pneumonia or meningitis can be rapidly identified with a single enzyme-conjugated preparation. This advantage of using only one labeled antibody has been recognized and applied in radioimmunoassays and fluorescent-antibody assays.
Such adaptation, however, requires the use of several antisera not yet commercially available. The identification of pneumococcus at the species level, for example, requires two antigenically distinct polyvalent (species-specific) anti-pneumococcal antibodies; the first (i.e., capture) antibody can be prepared in any convenient species. The second antibody, which both recognizes captured antigen and serves as a target for the enzyme-conjugated anti-globulin reagent, should be prepared in a second species to avoid interaction of the conjugate with the first (capture) antibody. The second antibody may be either polyvalent (species specific) or monovalent (serotype specific), and as long as all second antibody preparations are of the same species, only one conjugate is required. At present, the species-paired polyvalent anti-pneumococcus antisera needed for this assay are not available commercially. The potential clinical usefulness of this assay, when the required antisera become available, is considerable.
